drugset / Trial / NCT03446638
iCare 2: Personalized Genomic Mutation Informed Treatment of Patients With Myelodysplastic Syndromes
RandomizedParallel-groupOpen-labelTreatment
Summary
This open-label, randomized, parallel group phase II study will investigate the efficacy of computational biology-informed treatment vs. standard of care treatment for patients with relapsed or refractory myelodysplastic syndromes (MDS).
Timeline
- Start
- 2019-05
- Primary completion
- 2021-08
- Completion
- 2022-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cytarabine | Small molecule | 20 mg/m2 | Intravenous |
| Comparator | Cytarabine | Small molecule | 20 mg/m2 | Subcutaneous |
| Comparator | Cytarabine | Small molecule | 30 mg/m2 | Intravenous |
| Comparator | Cytarabine | Small molecule | 100 mg/m2 | Intravenous |
| Comparator | Cytarabine | Small molecule | 200 mg/m2 | Intravenous |
| Comparator | Cytarabine | Small molecule | 2000 mg/m2 | Intravenous |
| Comparator | Daunorubicin | Small molecule | 45 mg/m2 | Intravenous |
| Comparator | Daunorubicin | Small molecule | 60 mg/m2 | Intravenous |
| Comparator | Fludarabine | Small molecule | 30 mg/m2 | Intravenous |
| Comparator | Idarubicin | Small molecule | 9 mg/m2 | Intravenous |
| Comparator | Idarubicin | Small molecule | 12 mg/m2 | Intravenous |